EMD Serono Collaborates with US Government to Expand IVF Access
Rockville, MD – October 17, 2025 - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, has entered into a public-private partnership with the U.S. government to significantly broaden access to in vitro fertilization (IVF) treatments across the nation. The collaboration aims to address growing financial barriers preventing many individuals and couples from pursuing fertility care.
This initiative arrives amid increasing demand for IVF and escalating costs, impacting an estimated 12% of couples of reproductive age in the United States. The partnership will leverage EMD Serono’s financial support and expertise in reproductive medicine alongside federal resources to implement programs designed to reduce the financial burden of IVF, perhaps impacting tens of thousands seeking to start or expand their families. Details of the specific programs and funding allocations are expected to be released in the coming months.
EMD Serono’s commitment includes financial contributions to support patient assistance programs and initiatives focused on reducing the cost of fertility medications. The company will also work with government agencies to identify and address systemic barriers to IVF access, including insurance coverage limitations and geographic disparities in care availability. This collaboration builds upon EMD Serono’s existing efforts to support the fertility community through educational resources and patient advocacy programs.
“we beleive everyone deserves the prospect to build a family,” stated a company representative. “This partnership with the U.S.government is a crucial step towards making IVF more accessible and affordable for those who need it.” The long-term goal is to establish a enduring model for expanding IVF access and improving fertility care outcomes nationwide.
